|Bid||3.84 x 1800|
|Ask||4.00 x 100|
|Day's Range||3.63 - 3.81|
|52 Week Range||3.24 - 6.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 28, 2017 - Jul 31, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In January 2015, Incyte (INCY) entered an antibody discovery collaboration with Agenus (AGEN), which was later amended in February 2017. As per the amended agreement, the ongoing research programs for the development of checkpoint modulator antibodies targeted at GITR and OX40 have been converted from co-funded ones to being fully funded by Incyte. Additionally, the profit-sharing arrangement for these research programs has been converted into royalty-bearing programs.
Agenus Inc’s (NASDAQ:AGEN) announced its latest earnings update in December 2017, which indicated company earnings became less negative compared to the previous year’s level as a result of recent tailwindsRead More...
LEXINGTON, Mass. , April 11 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that three ...
LEXINGTON, Mass., March 29, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immune-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that members of the Company's leadership will present and host one-on-one meetings at two healthcare investment conferences in April. Jennifer Buell, Ph.D., Chief External Affairs and Communications Officer of Agenus, will present on Agenus and AgenTus at the Jefferies IO Cell Therapy Summit on April 3, 2018, at the Boston Harbor Hotel, Boston, Massachusetts. Corporate presentation is at 7:55 a.m. ET.
The Lexington, Massachusetts-based company said it had a loss of 35 cents per share. The biotechnology company posted revenue of $8.4 million in the period. For the year, the company reported that its ...
LEXINGTON, Mass. , March 15, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update ...
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Agenus Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018 at 11:00 AM Eastern Time. To listen ...
LEXINGTON, Mass. , March 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its fourth quarter ...
For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.Read More...
NEW YORK, Feb. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acacia ...
LEXINGTON, Mass., Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of its combination trial with its proprietary anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN2034) antibodies. This Phase 1/2 clinical trial launched in December 2017 and enrollment into the first cohort has been rapidly completed. The optimal combination dose and schedule will be evaluated in an expansion cohort of patients with inoperable cervical cancer who have relapsed after platinum-containing chemotherapy. In addition, we believe both agents are crucial for combinations with our portfolio of proprietary immune oncology therapeutics," said Garo Armen, Ph.D., Chairman and CEO of Agenus.
LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing ...
In 2018, the biotech industry is expected to witness a continuation of last year’s favorable trends. Noteworthy among them was the approval of Novartis’ (NYSE:NVS) Kymriah, the first cell-based gene therapy known as CAR-T therapy, which is an innovative treatment option for cancer. Spark Therapeutics’s Luxturna, the first gene therapy to treat a rare, inherited form of childhood blindness, was also approved last year.
BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day
We take a look at some biotech stocks that have witnessed an increase in their share price this year so far and look well positioned for the rest of 2018.